Determining how common amyloidosis is in trauma surgery patients
Official title: Prevalence of Amyloidosis in Trauma Patients Using Red Flags Tool
Run by Consorci Sanitari de l'Alt Penedès i Garraf · NCT06527521 · Data updated 2026-11-12
This study is trying to find out how common amyloidosis is in patients who are about to have trauma surgery by looking for certain warning signs that might show a higher risk.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 246 (estimated) |
| Sponsor | Consorci Sanitari de l'Alt Penedès i Garraf Academic / other |
| Locations | 1 site (Sant Pere de Ribes, Barcelona) |
| Status | Recruiting |
| Started | November 13, 2024 |
| Main results expected | August 2027 |
| Study ends | October 2027 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT06527521 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men and women over 65 or those with specific health histories that raise suspicion for amyloidosis.
✕Probably not a fit
Patients who have already been diagnosed with amyloidosis will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the prevalence of amyloidosis in patients scheduled for trauma surgery. It focuses on identifying individuals with specific 'red flags' that may indicate a higher risk of amyloidosis, such as age over 65, family history, and various cardiac and neurological conditions. Participants will be evaluated based on these criteria to better understand the frequency of this condition in a trauma setting.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and management of amyloidosis in trauma patients, improving patient outcomes.
How similar studies have gone: While the approach of assessing amyloidosis prevalence in trauma patients is relatively novel, similar studies have indicated the importance of identifying underlying conditions in surgical populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women included in the waiting list for scheduled trauma surgery with at least one of the following criteria defined as red flags: Over 65 years old; Possible family history of amyloidosis, Cardiac pathology: aortic stenosis, presence of left ventricular hypertrophy defined as interventricular septal thickness \> 12mm measured by echocardiography, history of previous brady- or tachyarrhythmias including cardiac conduction blocks, history of syncope or presyncope, pro BNP \> 300 in previous blood tests; History of sensory peripheral neuropathy; History of nephropathy without etiological diagnosis; History of liver disease without a clear cause. * Ability to cooperate in the necessary evaluations. * Signed informed consent for inclusion in the study, either by the participant or their legal representative. Exclusion Criteria: \- Participants previously diagnosed with amyloidosis cannot be included in the study.
Where it's running
-
Consorci Sanitari Alt Penedes i Garraf-Hospital Sant Camil
Sant Pere de Ribes, Barcelona, Spain Recruiting
Study contacts
- Principal investigator: Lidia Tikhomirova, MD — Csapg
- Study coordinator: Lidia Tikhomirova, MD
- Email: ltikhomirova@csapg.cat
- Phone: +34 938960025
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acoramidis for ATTR-CM: Cardiac Imaging Study
This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.
-
Heart-Healthy Rehab for Cardiac Amyloidosis
This study tests whether a 5-week supervised cardiac rehabilitation program can help people with cardiac amyloidosis improve exercise capacity and quality of life.
-
SCTC21C plus bortezomib, cyclophosphamide and dexamethasone for newly diagnosed systemic light-chain (AL) amyloidosis
This trial tests whether adding SCTC21C to standard bortezomib‑cyclophosphamide‑dexamethasone (VCd) helps people with newly diagnosed AL (light‑chain) amyloidosis achieve better hematologic responses and outcomes.
-
In-home cancer treatment with remote specialist support for patients in the Florida Panhandle
This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.
-
18F‑FT8 PET imaging for light‑chain (AL) cardiac amyloidosis
This project tests whether a new PET tracer, 18F‑FT8, can safely and clearly image light‑chain (AL) cardiac amyloidosis in adults with suspected or known disease and in healthy volunteers.
-
Belantamab Mafodotin with a chemotherapy combo for newly diagnosed AL amyloidosis
This study tests whether adding belantamab mafodotin to a regimen of cyclophosphamide, bortezomib, and dexamethasone can help adults with newly diagnosed AL amyloidosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.